Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 4

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 (2,129,685)  (3,430,061)  (3,535,248)                 LOSS FROM OPERATIONS  (702,509)  (1,337,622)  (1,932,220)  (1,157,482)                 FINANCE COSTS  (6,482)  (6,193)  (16,270)  (15,334)                 LOSS BEFORE TAX  (708,991)  (1,343,815)  (1,948,490)  (1,172,816)                 Tax expense  -   (1,555)  -   (77,207)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(708,991) $(1,345,370) $(1,948,490) $(1,250,023)                 Other comprehensive income                Foreign currency translation gain  3,216   1,046,789   442,453   839,344                  COMPREHENSIVE LOSS $(705,775) $(298,581) $(1,506,037) $(410,679)                 Earnings per share - Basic and diluted  (0.395)  (0.749)  (1.085)  (0.704)Weighted average number of common stocks outstanding, Basic and Diluted #  1,796,597   1,796,766   1,796,597   1,776,766 

# Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 1-for-10 reverse stock split effected on April 7, 2025 on a retroactive basis as described in Note 12.

See accompanying notes to the condensed consolidated financial statements.

 6Table of Contents

BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY 

AS OF SEPTEMBER 30, 2025 AND 2024 

(Amount expressed in United States Dollars (“US$)) 

(Unaudited)

  Common stock  Additional      Accum